-
公开(公告)号:US10085940B2
公开(公告)日:2018-10-02
申请号:US14232332
申请日:2012-07-12
申请人: Alberto A. Gabizon , Yechezkel Barenholz , Hilary Shmeeda , John Maher , Ana Catarina Parente Pereira
发明人: Alberto A. Gabizon , Yechezkel Barenholz , Hilary Shmeeda , John Maher , Ana Catarina Parente Pereira
IPC分类号: A61K31/704 , A61K9/127 , A61K31/663 , A61K38/20 , A61K45/06 , A61K35/15 , A61K35/17 , A61K47/55 , A61K47/69 , A61K39/00
摘要: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as γδ T-cells.